FLT3 inhibitor and venetoclax therapy in elderly patients with relapsed/refractory FLT3-ITD+ AML: A report of three cases

Leukemia Research Reports 2026 Open access

Read full text
Authors: Daisuke Ikeda, Satoshi Uchiyama, Yong‐Mei Guo, Nobue Sato, Hirotaka Nakamura, Akihito Nagata, Chi Song-Gi, Yosuke Minami, Junichiro Yuda
DOI: 10.1016/j.lrr.2026.100591
Cited by: 1
References: 22

Abstract

This case report examines three patients with relapsed/refractory FLT3-ITD + acute myeloid leukemia (AML) treated with FLT3 inhibitors (FLT3i) and venetoclax (VEN). While the combination therapy showed promising antileukemic activity, all patients experienced severe myelosuppression, leading to treatment interruptions. Two patients died following disease progression after therapy discontinuation, while one maintained remission with an alternating treatment schedule. These cases highlight the importance of minimizing treatment interruptions while balancing infection risks and suggest that combination or sequential therapy with VEN and FLT3i may be effective for relapsed/refractory (R/R) FLT3-ITD + AML when treatment duration and dosing are properly managed.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Chronic Lymphocytic Leukemia Research Hemoglobinopathies and Related Disorders

Publication details

Journal / source
Leukemia Research Reports
Publisher
Elsevier BV
Volume
25
Pages
100591–100591
Publication date
1 January 2026
Language
EN